Combination PI3K and NOS targeted therapy for metaplastic breast cancer

被引：0
|
作者：
Reddy, T. [1 ]
Rosato, R. [1 ]
Guzman, L. [1 ]
Qian, W. [1 ]
Zhou, J. [1 ]
Piwnica-Worms, H. [2 ]
Moulder, S. [3 ]
Chang, J. [1 ]
机构：
[1] Houston Methodist Res Inst, Ctr Canc, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Canc Biol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Breast Oncol, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
179
引用
收藏
页码：S49 / S50
页数：2
相关论文
共 50 条
  • [41] SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
    Tran, Arthur-Quan
    Sullivan, Stephanie A.
    Chan, Leo Li-Ying
    Yin, Yajie
    Sun, Wenchuan
    Fang, Ziwei
    Dugar, Sundeep
    Zhou, Chunxiao
    Bae-Jump, Victoria
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [42] Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy
    Mustafi, Sushmita
    Camarena, Vladimir
    Qureshi, Rehana
    Sant, David W.
    Wilkes, Zachary
    Bilbao, Daniel
    Slingerland, Joyce
    Kesmodel, Susan B.
    Wang, Gaofeng
    THERANOSTICS, 2021, 11 (08): : 3552 - 3564
  • [43] The present and future of PI3K inhibitors for cancer therapy
    Pau Castel
    Eneda Toska
    Jeffrey A. Engelman
    Maurizio Scaltriti
    Nature Cancer, 2021, 2 : 587 - 597
  • [44] The present and future of PI3K inhibitors for cancer therapy
    Castel, Pau
    Toska, Eneda
    Engelman, Jeffrey A.
    Scaltriti, Maurizio
    NATURE CANCER, 2021, 2 (06) : 587 - 597
  • [45] Targeting the PI3K signaling pathway in cancer therapy
    Bartholomeusz, Chandra
    Gonzalez-Angulo, Ana Maria
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (01) : 121 - 130
  • [46] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [47] PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
    Vladimir Sapon-Cousineau
    Sasha Sapon-Cousineau
    Sarit Assouline
    Current Treatment Options in Oncology, 2020, 21
  • [48] PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
    Sapon-Cousineau, Vladimir
    Sapon-Cousineau, Sasha
    Assouline, Sarit
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (06)
  • [49] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    CANCER RESEARCH, 2015, 75
  • [50] A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
    Ischenko, Irene
    Petrenko, Oleksi
    Hayman, Michael J.
    ONCOTARGET, 2015, 6 (18) : 15814 - 15827
12345